Results

Jounce Therapeutics Inc.

01/13/2021 | Press release | Distributed by Public on 01/13/2021 07:06

Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with[...]